Search for Terms or Answers
Data made public by the Centers for Medicare & Medicaid Services shows that drug and device makers made nearly $8.2 billion in payments to U.S. physicians and teaching hospitals in the last year. Since 2013, CMS has been tracking physician payments as part of the Affordable Care Act.
The FDA has approved both IV and SC ORENCIA (abatacept) for the treatment of adults with active Psoriatic Arthritis.
It is well-known that patients with systemic autoimmune diseases are at risk for Pneumocystis jirovecii pneumonia (PJP) and although infrequent, it carries a high mortality. A new study shows lymphopenia and steroid use increases the risk of PJP.
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Pianta, et al have published their findings in the Journal of Clinical Investigation showing that two novel autoantigens, GNS and FLNA, are highly expressed in synovium and share a sequence homology with gut microbesa; thereby providing a potential link between gut mucosal and joint immunity in rheumatoid arthritis.
Researchers from Augusta University have examined exosomes from patients with knee osteoarthritis (OA) to enhance our molecular understanding of the pathogenesis of OA. (Citation source http://buff.ly/2tuDZ3v)
Dr. Sharad Lakhanpal, President of the American College of Rheumatology has responded to the Senate's proposed changes to healthcare coverage in the USA.
It is a common practice for rheumatologists to discuss medication-related teratogenicity and disease implications in case of pregnancy. Yet, discussion of breastfeeding are often omitted.
Dr. Janet Pope reviews her favorite and least favorite presentations and abstracts from EULAR 2017.
Based on recent clinical trials, the makers of golimumab have petitioned the FDA for new indications in PsA and AS. Trials for PsA (GO-VIBRANT) and AS (GO-ALIVE) were presented at last weeks EULAR 2017 meeting in Madrid, Spain.
Dr. Jack Cush reviews his approach to attending and getting the most out of ACR or EULAR Congress meetings.
The Canadian Medical Association Journal has studied the costs of prescription drugs in 10 high-income countries (seven European countries, Australia, Canada and New Zealand) and found that many of these medicines varied by more than 600%.
Bone turnover markers (BTMs) have been eyed for decades as potential monitoring tools in osteoporosis.
Therapeutic options for cutaneous psoriasis (and psoriatic arthritis as well) are rapidly expanding. Lancet has published the impressive results of two phase III trials of tildrakizumab, a IgG1 antibody against interleukin 23 p19, in patients with active chronic plaque psoriasis.
The American College of Rheumatology has partnered with the American Association of Hip and Knee Surgeons to develop consensus-based guidelines for perioperative management of antirheumatic therapies for patients with rheumatic diseases who plan to undergo total joint replacement.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
